Open AccessPharmacogenetics of hypoglycemic agents
Author(s) -
Ирина Владимировна Кононенко,
Alexander Yur'evich Mayorov,
Ekaterina Koksharova,
Marina Shestakova
Publication year - 2015
Publication title -
saharnyj diabet
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.155
H-Index - 12
eISSN - 2072-0378
pISSN - 2072-0351
DOI - 10.14341/dm7681
Subject(s) - medicine , sulfonylurea , metformin , pharmacogenetics , glycemic , diabetes mellitus , pharmacology , glucagon like peptide 1 , troglitazone , bioinformatics , type 2 diabetes , endocrinology , receptor , gene , genotype , genetics , biology , peroxisome
Despite the increase in the number of hypoglycemic agents, 35%–40% of patients with diabetes are unable to achieve adequate glycemic control. One of the reasons is the genetic heterogeneity of diabetes mellitus, requiring different treatment approaches; however, the individual metabolic features and sensitivity to drugs also affect the therapeutic effectiveness. The review presents the main results of pharmacogenetic research of several antidiabetic drugs: metformin, sulfonylurea, agonists of glucagon-like peptide-1 and thiazolidinediones.